Susvimo (ranibizumab port delivery system) / Roche  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Susvimo (ranibizumab port delivery system) / Roche
Belvedere, NCT04853251: A Study Assessing Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)

Recruiting
4
185
US
SUSVIMO Port Delivery System with ranibizumab (PDS), LUCENTIS (ranibizumab injection)
Genentech, Inc.
Neovascular Age-related Macular Degeneration
04/27
04/27

Download Options